US › Healthcare

Apellis Pharmaceuticals Inc (APLS)

US · Healthcare · Biotechnology

$3.37-0.52%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$268.3M
Revenue YoY
+60.9%
Net profit
$18.7M
Profit YoY
+120.2%
EPS
$0.15
EPS estimate
$-0.36
Net margin
7.0%

EPS came in at 0.15 against a street estimate of -0.36 — a beat of 141.7%.

Key statistics

Market cap
$5.25B
P/E
38.3
Forward P/E
46.3
P/B
12.66
Book value
$3.24
EPS (TTM)
$1.07
52-week high
$41.14
52-week low
$3.05
50-day MA
$33.60
200-day MA
$26.15
Beta
-0.25

Analyst view

Analysts rate Apellis Pharmaceuticals Inc a buy (14 buy, 8 hold, 0 sell out of 22) with an average price target of $40.92.

Shareholding

Insiders
11.37%
Institutions
110.43%

Largest institutional holders

FundStake
BlackRock Inc10.57%
venBio Select Advisor LLC9.55%
Morgan Stanley - Brokerage Accounts7.84%
State Street Corp5.35%
UBS Group AG4.85%
Vanguard Portfolio Management, LLC4.22%
Pentwater Capital Management LP4.10%
Vanguard Capital Management, LLC3.73%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Apellis Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.